Resistance of hepatocellular carcinoma to Sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and Sorafenib in nanoparticles

Binquan Wu,Amin Li,Yinci Zhang,Xueke Liu,Shuping Zhou,Huaiyong Gan,Shiyu Cai,Yong Liang,Xiaolong Tang

Resistance of hepatocellular carcinoma to Sorafenib can be overcome with co-delivery of PI3K/mTOR inhibitor BEZ235 and Sorafenib in nanoparticles

2020

Binquan Wu
Amin Li
Yinci Zhang
Xueke Liu
Shuping Zhou
Huaiyong Gan
Shiyu Cai
Yong Liang
Xiaolong Tang

AbstractBackground: The combination of BEZ235 with sorafenib (SFB) enhances anti-hepatocellular carcinoma (HCC) efficacy of the two agents. However, pharmacokinetic profiles in vivo and different e...

Keywords:

In vivo
Materials science
Sorafenib
Hepatocellular carcinoma
PI3K/mTOR Inhibitor BEZ235
Apoptosis
Carcinoma
Pharmacokinetics
Pharmacology
co delivery

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations